2 weeks Ago By Defense World Staff
IQVIA ( NYSE:IQV – Get Free Report ) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Friday. Several other analysts also recently commented on IQV.
Truist Financial increased their target price on IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd.
Robert W. Baird upped their target price on shares of IQVIA from $251.00 to $256.
00 and gave the company a “neutral” rating in a research note on Friday, September 20th. Evercore ISI boosted their price objective on shares of IQVIA from $230.00 to $270.
00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. UBS Group raised their target price on shares of IQVIA from $295.00 to $300.
00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Finally, JPMorgan Chase & Co. increased their price target on IQVIA from $260.
00 to $288.00 and gave the company an “overweight” rating in a report on Monday, August 5th. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock.
According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $267.00.
Get Our Latest Research Report on IQV IQVIA Stock Down 0.7 % IQVIA ( NYSE:IQV – Get Free Report ) last released its earnings results on Monday, July 22nd. The medical research company reported $2.
64 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07.
IQVIA had a return on equity of 28.59% and a net margin of 9.39%.
The firm had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion.
During the same period in the prior year, the firm posted $2.22 earnings per share. The company’s quarterly revenue was up 2.
3% on a year-over-year basis. As a group, research analysts expect that IQVIA will post 10.25 EPS for the current year.
Insider Activity In other news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.
00. Following the completion of the transaction, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88.
The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink . Company insiders own 1.60% of the company’s stock.
Hedge Funds Weigh In On IQVIA Institutional investors and hedge funds have recently modified their holdings of the stock. Jennison Associates LLC boosted its stake in IQVIA by 7.3% during the first quarter.
Jennison Associates LLC now owns 140,914 shares of the medical research company’s stock worth $35,636,000 after buying an additional 9,578 shares during the period. Cadian Capital Management LP purchased a new position in shares of IQVIA during the fourth quarter valued at approximately $70,108,000. Nomura Holdings Inc.
bought a new position in shares of IQVIA during the fourth quarter valued at approximately $857,000. PGGM Investments raised its holdings in shares of IQVIA by 55.8% in the second quarter.
PGGM Investments now owns 12,073 shares of the medical research company’s stock worth $2,553,000 after buying an additional 4,326 shares during the period. Finally, Fiduciary Alliance LLC bought a new stake in shares of IQVIA during the 1st quarter worth approximately $1,864,000. Hedge funds and other institutional investors own 89.
62% of the company’s stock. About IQVIA ( Get Free Report ) IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More Five stocks we like better than IQVIA What Are Growth Stocks and Investing in Them Can Costco Stock Hit New Highs as Interest Rates Drop? Why is the Ex-Dividend Date Significant to Investors? These 3 Stocks Show How to Navigate Declining Consumer Confidence Business Services Stocks Investing MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy? Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter ..
